The prevalence and outcome of short-acting β2-agonists overuse in asthma patients in Taiwan.
Cheng-Yi WangChih-Cheng LaiYa-Hui WangHao-Chien WangPublished in: NPJ primary care respiratory medicine (2021)
This study aims to investigate the prevalence of short-acting β2-agonist (SABA) overuse in asthma and the associated risk of acute exacerbation and mortality in Taiwan. We used the Taiwanese pay-for-performance asthma program database, which included patients aged between 12 and 100 years who were enrolled in the program between 2001 and 2015. Among a total of 218,039 patients, 34,641 (15.9%) patients are classified as SABA over-users. Compared with patients who did not receive inhaled corticosteroids (ICS) and collected ≤2 canisters, SABA over-users had a higher risk of severe exacerbations. SABA over-users had a higher risk of all-cause mortality compared with patients who did not receive ICS and collected ≤2 canisters. The overall prevalence of SABA overuse in Taiwan is 15.9%, and this is even higher in concomitant ICS users. In addition, the overuse of SABA is associated with an increased risk of severe exacerbation and death.
Keyphrases
- end stage renal disease
- chronic obstructive pulmonary disease
- ejection fraction
- newly diagnosed
- chronic kidney disease
- peritoneal dialysis
- risk factors
- type diabetes
- prognostic factors
- emergency department
- cystic fibrosis
- lung function
- early onset
- air pollution
- health insurance
- extracorporeal membrane oxygenation
- electronic health record